INDO US BIOTECH
Back to Balance Sheet
|
INDO US BIOTECH Last 5 Year Total Non-Current Liabilities History
[Standalone]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹2.29 Cr | ₹3.59 Cr | ₹2.09 Cr | ₹4.07 Cr | ₹3.92 Cr |
What is the latest Total Non-Current Liabilities ratio of INDO US BIOTECH ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2025 | ₹2.29 Cr |
| Mar2024 | ₹3.59 Cr |
| Mar2023 | ₹2.09 Cr |
| Mar2022 | ₹4.07 Cr |
| Mar2021 | ₹3.92 Cr |
How is Total Non-Current Liabilities of INDO US BIOTECH Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2025 | ₹2.29 Cr | -36.14 | |
| Mar2024 | ₹3.59 Cr | 71.41 | |
| Mar2023 | ₹2.09 Cr | -48.61 | |
| Mar2022 | ₹4.07 Cr | 3.96 | |
| Mar2021 | ₹3.92 Cr | - | |
Compare Total Non-Current Liabilities of peers of INDO US BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| INDO US BIOTECH | ₹146.7 Cr | -2.9% | -8.2% | -46.3% | Stock Analytics | |
| KAVERI SEED COMPANY | ₹3,479.3 Cr | -3.7% | -7.2% | -34.8% | Stock Analytics | |
| VENKYS (INDIA) | ₹2,254.0 Cr | -2.7% | -6.4% | 7.3% | Stock Analytics | |
| AVT NATURAL PRODUCTS | ₹1,443.2 Cr | 6.2% | 5.7% | 19.1% | Stock Analytics | |
| BOMBAY SUPER HYBRID SEEDS | ₹881.5 Cr | 0.4% | -7.7% | NA | Stock Analytics | |
| MANGALAM GLOBAL ENTERPRISE | ₹526.0 Cr | 1.9% | 2.9% | -12.3% | Stock Analytics | |
INDO US BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| INDO US BIOTECH | -2.9% |
-8.2% |
-46.3% |
| SENSEX | 0.8% |
-4.8% |
-10.5% |
You may also like the below Video Courses